Analyses of response by PD-L1 and LAG-3 within the MSS population in part 2 of the study were exploratory and limited in sample size, and validation of these biomarkers in a larger population of patients with CRC would be valuable, in addition to evaluation of other biomarkers of interest such as tumour mutational burden and MSS status. The gene discussed is LAG3; the disease is neoplasm.